WallStSmart

Merck & Company Inc (MRK)vsOSR Holdings Inc (OSRH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2501916% more annual revenue ($65.77B vs $2.63M). MRK leads profitability with a 13.6% profit margin vs 0.0%. OSRH trades at a lower P/E of 13.4x. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

OSRH

Avoid

25

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 6.0Quality: 5.0
Piotroski: 4/9Altman Z: 0.79
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for OSRH.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

OSRH3 strengths · Avg: 9.3/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

P/E RatioValuation
13.4x8/10

Attractively priced relative to earnings

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

OSRH4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.13M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-14.7%2/10

ROE of -14.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : OSRH

The strongest argument for OSRH centers on Price/Book, Debt/Equity, P/E Ratio.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : OSRH

The primary concerns for OSRH are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

OSRH carries more volatility with a beta of 0.61 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

OSR Holdings Inc

HEALTHCARE · BIOTECHNOLOGY · USA

OSR Holdings Inc. is a prominent provider of integrated managed services, specializing in asset management and financial advisory solutions tailored for institutional clients. Leveraging cutting-edge technology and strategic collaborations, the company enhances operational efficiency while expanding its diverse service portfolio. Committed to sustainable growth and client-centric value creation, OSR Holdings distinguishes itself through innovation and exceptional service quality. With a proactive approach to emerging market opportunities, the firm upholds a robust risk management framework, ensuring long-term stability and success for its stakeholders.

Want to dig deeper into these stocks?